BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

Cancer

Volumn 120, Issue 15, 2014, Pages 2316-2324

  Yaeger, Rona ^a   Cercek, Andrea ^a   Chou, Joanne F ^a   Sylvester, Brooke E ^a   Kemeny, Nancy E ^a   Hechtman, Jaclyn F ^a   Ladanyi, Marc ^a   Rosen, Neal ^a   Weiser, Martin R ^a   Capanu, Marinela ^a   Solit, David B ^a   D'Angelica, Michael I ^a   Vakiani, Efsevia ^a   Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

5 bisphosphate 3 kinase; BRAF; catalytic subunit alpha); colorectal cancer; liver resection; PIK3CA (phosphatidylinositol 4; prognosis

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; LUNG LOBECTOMY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVARIECTOMY; OVARY METASTASIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA GENE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SEX DIFFERENCE; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; WEDGE RESECTION; COLORECTAL NEOPLASMS; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; METASTASECTOMY; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84904736732     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28729     Document Type: Article

References (27)

1. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487: 330-337.
2. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318: 1108-1113.
3. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study. Br J Cancer. 2001; 85: 692-696.
4. Imamura Y, Morikawa T, Liao X, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012; 18: 4753-4763.
5. Peeters M, Douillard JY, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol. 2013; 31: 759-765.
6. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML,. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000; 9: 1193-1197.
7. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011; 117: 4623-4632.
8. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012; 30: 2956-2962.
9. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012; 18: 890-900.
10. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28: 466-474.
11. Van Cutsem EL, Folprecht G, Nowacki M, et al. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [abstract]. J Clin Oncol. 2010; 28:15s Abstract 3570.
12. Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011; 104: 856-862.
13. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38: 787-793.
14. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A,. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 2010; 127: 367-380.
15. Popovici V, Budinska E, Tejpar S, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol. 2012; 30: 1288-1295.
16. Arcila M, Lau C, Nafa K, Ladanyi M,. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn. 2011; 13: 64-73.
17. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH,. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309-318; discussion 318-321.
18. Cox DR,. Regression models and life tables. J R Stat Soc B. 1972; 20: 187-220.
19. Gray RJ,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
20. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD,. A note on competing risks in survival data analysis. Br J Cancer. 2004; 91: 1229-1235.
21. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009; 58: 90-96.
22. Baba Y, Nosho K, Shima K, et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer. 2011; 117: 1399-1408.
23. Kato S, Iida S, Higuchi T, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer. 2007; 121: 1771-1778.
24. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012; 18: 2257-2268.
25. Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ, Oates J,. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer. 1999; 79: 1800-1805.
26. Catalano V, Loupakis F, Graziano F, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer. 2009; 100: 881-887.
27. Teng HW, Huang YC, Lin JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol. 2012; 106: 123-129.